Johnson & Johnson stock: Prostate combo advances to Phase 3

Published on 11/13/2026 at 16:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Johnson & Johnson stock gains as a prostate drug combo enters Phase 3. Early PSA responses support the next test, while safety remains key.

Pipeline milestone meets a larger test

The pasritamig and JNJ-9401 combination is entering the Phase 3 KLK2-comPAS study for advanced prostate cancer.
Early results showed deep PSA reductions, but the recommended-regimen analysis covered only 15 patients.
Phase 3 efficacy, durability and regulatory progress remain the key milestones for investors.

Johnson & Johnson, US4781601046, Illustration mit AI erstellt.

Johnson & Johnson is moving its pasritamig and JNJ-9401 combination into a larger clinical test after early prostate-cancer data showed deep PSA reductions. The company announced the Phase 1 findings on November 8, 2026, in a Johnson & Johnson press release.

Early signal, larger clinical test

At the recommended regimen, 11 of 15 patients achieved a reduction of at least 50 percent in prostate-specific antigen, or PSA. Seven patients recorded reductions of at least 90 percent, four reached undetectable PSA levels, and all seven with the deepest reductions remained on treatment for more than six months without disease progression.

The regimen combines pasritamig, a KLK2xCD3 bispecific antibody, with JNJ-9401, a PSMAxCD28 costimulatory bispecific antibody. Johnson & Johnson is evaluating the combination in the Phase 3 KLK2-comPAS study for metastatic castration-resistant prostate cancer, testing whether adding JNJ-9401 to pasritamig can improve outcomes.

Safety remains an investor focus

The early analysis reported no Grade 3 or higher treatment-related adverse events, dose-limiting toxicities, treatment-related discontinuations or treatment-related deaths at the recommended regimen. Cytokine release syndrome occurred in three patients, with all cases classified as Grade 1 temporary fever. The company said the six-week dosing schedule could support outpatient treatment.

The findings came from a heavily pretreated population with a median of four prior systemic treatment lines. Because the recommended-regimen analysis involved a small group, the Phase 3 studies will be important for assessing whether the initial PSA signal translates into broader and durable clinical benefit.

Stock advances from the prior report

Johnson & Johnson stock traded at 259.75 euros on Lang & Schwarz at 16:32 CET on Friday, November 13, 1.23 percent above the Xetra close of Thursday, November 12. Since the November 12 report, the stock has risen 1.78 percent from 255.20 euros at 14:12 CET to the latest quote.